Identification of a Functional Apolipoprotein E Promoter Polymorphism Regulating Plasma Apolipoprotein E Concentration

Identification of a functional apolipoprotein E promoter polymorphism regulating plasma apolipoprotein E concentration.

OBJECTIVE There is compelling evidence that the plasma apolipoprotein E (APOE) concentration, in addition to the APOE ε2/ε3/ε4 genotype, influences plasma lipoprotein levels, but the functional genetic variants influencing the plasma APOE concentration have not been identified. APPROACH AND RESULTS Genome-wide association studies in 2 cohorts of healthy, middle-aged subjects identified the AP...

Association of Apolipoprotein E Polymorphism with Susceptibility to Multiple Sclerosis

Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a).

In a group of 303 healthy Caucasian adults of both sexes we studied the influence of the apolipoprotein E (apo E) polymorphism on plasma levels of Lipoprotein(a) (Lp(a). The APOE*2 allele was found to decrease the mean plasma Lp(a) level by 24.8%, whereas the APOE*4 allele increased the mean Lp(a) level by 25.7%. These effects were parallel to the effect of apo E polymorphism on plasma choleste...

Apolipoprotein E Polymorphism in an Iranian Hypercholestrolemic Population

Apolipoprotein E (apo E) is a structural constituent of several serum lipoprotein classes. It plays an important role in lipid metabolism by acting as a ligand for low-density lipoprotein (LDL) and chylomicron remnant receptors. Three common alleles called e2, e3 and e4 have been described, which code for three protein isoforms (E2, E3 and E4). The polymorphism is clinically significant, and it...

Apolipoprotein E polymorphism and plasma cholesterol response to probucol.

Probucol has been shown to be an effective and well-tolerated cholesterol-lowering drug. However, response in terms of cholesterol reduction has been shown to vary significantly among individuals. The purpose of this study was to assess the role of apolipoprotein E polymorphism in determining this variation. A retrospective study of 89 hypercholesterolemic type II patients who had been treated ...